Oxygen-enriched water may modestly lower HbA1c in type 2 diabetes
Conclusión Clave:
This 12-week trial tested oxygen-enriched ELO water as an add-on therapy in adults with type 2 diabetes. HbA1c fell modestly in the ELO group, especially by week 6 compared with placebo, but fasting glucose and body weight did not clearly improve.
Estudio de un Vistazo
Qué se estudió
Oxygen-enriched ELO water as add-on therapy for adults with type 2 diabetes
Participantes
Young Adult (19–39), Middle Aged (40-64), Older Adults (65+)
Male, Female
with T2 Diabetes
Intervención
Oxygen-enriched water
Resultados
HbA1c, Fasting blood sugar (FBS), Body weight, Hypoglycemia events, Adverse events incidence
Financiamiento
No Patrocinado por la Industria
Guarda este estudio y agrega notas a tu biblioteca de investigación.
Efectos Principales
HbA1c ↓ (ELO water -0.3 ± 0.7% at 12 weeks)
Fasting plasma glucose → (no significant change in either group)
Body weight → (no significant change in either group)
Resumen de Evidencia
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Oxygen-enriched water (Supplements) |  Adverse events incidence (Safety) | Uncertain | Limited |
Oxygen-enriched water (Supplements) |  Body weight (Weight & Anthropometrics) | Uncertain | Limited |
Oxygen-enriched water (Supplements) |  Fasting blood sugar (FBS) (Glycemic Control) | No Change | Limited |
Oxygen-enriched water (Supplements) | HbA1c (Glycemic Control) | Decrease | Limited |
Oxygen-enriched water (Supplements) | Hypoglycemia events (Safety) | Uncertain | Limited |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Tener en Cuenta
- Short 12-week proof-of-concept trial Commercial sponsorship by the ELO water manufacturer Small HbA1c change with no significant week-12 between-group difference in Table 1 No direct human measurements of tissue oxygenation, mitochondrial function, or insulin resistance
Entre Líneas
- Short 12-week proof-of-concept trial Commercial sponsorship by the ELO water manufacturer Small HbA1c change with no significant week-12 between-group difference in Table 1 No direct human measurements of tissue oxygenation, mitochondrial function, or insulin resistance
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.